IBK Investment & Securities, EstiPharm Target Price Raised to 200,000 Won... Expectation of Profitability Improvement
IBK Investment & Securities raised EstiPharm's target price to 200,000 won, citing expectations for improved profitability in the second quarter.
How this call is verified
▲ Bullish call was checked against the actual BTC price 24h later: ✗ Miss (-1.69%).
Bar: BTC ±1% within 24h · every verdict lands on the public ledger
Key takeaway
"IBK Investment & Securities, EstiPharm Target Price Raised to 200,000 Won... Expectation of Profitability Improvement" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 70 out of 100. IBK Investment & Securities raised EstiPharm's target price to 200,000 won, citing expectations for improved profitability in the second quarter. Reported by TokenPost on July 08, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 51.3%.